These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 34644561)
1. Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome. Ho JJD; Cunningham TA; Manara P; Coughlin CA; Arumov A; Roberts ER; Osteen A; Kumar P; Bilbao D; Krieger JR; Lee S; Schatz JH Cell Rep; 2021 Oct; 37(2):109806. PubMed ID: 34644561 [TBL] [Abstract][Full Text] [Related]
2. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation. Rubio CA; Weisburd B; Holderfield M; Arias C; Fang E; DeRisi JL; Fanidi A Genome Biol; 2014; 15(10):476. PubMed ID: 25273840 [TBL] [Abstract][Full Text] [Related]
3. Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol. Müller C; Obermann W; Schulte FW; Lange-Grünweller K; Oestereich L; Elgner F; Glitscher M; Hildt E; Singh K; Wendel HG; Hartmann RK; Ziebuhr J; Grünweller A Antiviral Res; 2020 Mar; 175():104706. PubMed ID: 31931103 [TBL] [Abstract][Full Text] [Related]
4. Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules. Singh K; Lin J; Lecomte N; Mohan P; Gokce A; Sanghvi VR; Jiang M; Grbovic-Huezo O; Burčul A; Stark SG; Romesser PB; Chang Q; Melchor JP; Beyer RK; Duggan M; Fukase Y; Yang G; Ouerfelli O; Viale A; de Stanchina E; Stamford AW; Meinke PT; Rätsch G; Leach SD; Ouyang Z; Wendel HG Cancer Res; 2021 Apr; 81(8):2002-2014. PubMed ID: 33632898 [TBL] [Abstract][Full Text] [Related]
5. Amidino-Rocaglates: A Potent Class of eIF4A Inhibitors. Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508 [TBL] [Abstract][Full Text] [Related]
6. Total synthesis of a biotinylated rocaglate: Selective targeting of the translation factors eIF4AI/II. Chambers JM; Lindqvist LM; Savage GP; Rizzacasa MA Bioorg Med Chem Lett; 2016 Jan; 26(2):262-264. PubMed ID: 26718843 [TBL] [Abstract][Full Text] [Related]
7. Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor. Iwasaki S; Floor SN; Ingolia NT Nature; 2016 Jun; 534(7608):558-61. PubMed ID: 27309803 [TBL] [Abstract][Full Text] [Related]
16. Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A. Chen M; Asanuma M; Takahashi M; Shichino Y; Mito M; Fujiwara K; Saito H; Floor SN; Ingolia NT; Sodeoka M; Dodo K; Ito T; Iwasaki S Cell Chem Biol; 2021 Apr; 28(4):475-486.e8. PubMed ID: 33296667 [TBL] [Abstract][Full Text] [Related]
17. Stress Granule-Inducing Eukaryotic Translation Initiation Factor 4A Inhibitors Block Influenza A Virus Replication. Slaine PD; Kleer M; Smith NK; Khaperskyy DA; McCormick C Viruses; 2017 Dec; 9(12):. PubMed ID: 29258238 [TBL] [Abstract][Full Text] [Related]
18. MATRIX platform to analyze translation machinery remodeling in glioblastoma cells. Ho JJD; Cunningham TA; Krieger JR; Schatz JH; Lee S STAR Protoc; 2022 Dec; 3(4):101919. PubMed ID: 36595908 [TBL] [Abstract][Full Text] [Related]
19. Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status. Chu J; Cencic R; Wang W; Porco JA; Pelletier J Mol Cancer Ther; 2016 Jan; 15(1):136-41. PubMed ID: 26586722 [TBL] [Abstract][Full Text] [Related]
20. 1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK properties. Nilewski C; Michels TD; Packard GK; Xiang AX; Sprengeler PA; Eam B; Fish S; Thompson PA; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Ernst JT; Reich SH Bioorg Med Chem Lett; 2021 Sep; 47():128111. PubMed ID: 34353608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]